Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1beta via NO-dependent pathway

International Journal of Cardiology
Xiao-Gang GuoJong-Dae Lee

Abstract

Angiotensin-converting enzyme (ACE) inhibitors are widely used in treatment of heart failure, but little is known regarding whether ACE inhibitors regulate the activity of matrix metalloproteinases (MMPs) and the tissue inhibitor of MMPs (TIMPs) in cardiac cells. The purpose of this study was to determine the ability and possible signal pathway involved of imidaprilat, an ACE inhibitor, to modulate MMP-2 and TIMP-2 in human cardiac fibroblasts in the presence of interleukin (IL)-1beta. Using gelatin zymography and RT-PCR and Griess analysis,we found that IL-1beta increased the MMP-2 activity and transcription and nitric oxide(NO) production from supernatant of culture medium. These effects of IL-1beta were inhibited by imidaprilat or the NO synthase inhibitor, L-NMMA. Sodium nitroprusside (SNP), an exogenous NO donor, prevented significantly the effects of imidaprilat on MMP-2 inhibition. Imidaprilat alone didn't affect MMP-2 activity and expression. Neither IL-1beta nor imidaprilat has no effect on TIMP-2 transcription in cardiac fibroblasts. The current study demonstrates imidaprilat inhibits MMP-2 activity and expression in human cardiac fibroblasts induced by IL-1beta via NO-dependent pathway. These data suggest that the be...Continue Reading

References

Jan 1, 1989·Journal of Molecular and Cellular Cardiology·M EghbaliM A Giambrone
Mar 1, 1988·Journal of Molecular and Cellular Cardiology·M EghbaliO O Blumenfeld
Oct 1, 1982·Analytical Biochemistry·L C GreenS R Tannenbaum
Dec 1, 1993·Kidney International·D SorbiL Arbeit
Mar 11, 1999·The American Journal of Cardiology·P AukrustL Gullestad
May 13, 1999·Biochimica Et Biophysica Acta·M P Murphy
Oct 12, 2001·European Journal of Heart Failure·S AdamopoulosD T Kremastinos
Oct 13, 2001·Trends in Cardiovascular Medicine·R T Lee
Feb 20, 2002·Journal of Molecular and Cellular Cardiology·Ute SeelandMichael Böhm
Mar 23, 2002·Circulation Research·Francis G Spinale
May 24, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Bin TianRobert J Bache
May 31, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Shunji HayashidaniAkira Takeshita
Jan 24, 2004·Heart Failure Reviews·Toshihiro TsurudaJohn C Burnett

❮ Previous
Next ❯

Citations

Jul 3, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Anna M Wasilewska, Walentyna M Zoch-Zwierz
May 10, 2013·Vascular Health and Risk Management·Thomas P VacekSuresh C Tyagi
Apr 21, 2010·Heart Failure Reviews·Mona HedayatNima Rezaei
May 23, 2009·Pharmacology & Therapeutics·Karen E Porter, Neil A Turner
Oct 29, 2020·European Journal of Clinical Investigation·Tetsuji MorishitaHiroshi Tada
Apr 9, 2021·Advanced Drug Delivery Reviews·Mengrui LiuKe Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis